Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2016 by Memorial Sloan Kettering Cancer Center
Sponsor:
Collaborators:
Eli Lilly and Company
M.D. Anderson Cancer Center
City of Hope National Medical Center
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT01025089
First received: December 2, 2009
Last updated: October 24, 2016
Last verified: October 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: December 2017
  Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)